INCLIVA   Report issue

Academic/Hospital Phase 2
Founded: Valencia Spain

Organization Overview

First Clinical Trial
2018
NCT03482362
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

INCLIVA | INCLIVA-Hospital Clínico Universitario

Active Ingredients

Drugs in Phase 2 Trials (3)

galunisertib (1 trial)

ly3200882 (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Other Trials (1)

dark chocolate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4